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Abstract: Radiotherapy plays an important role in the management 
of lung cancer, with over 50% of patients receiving this modality at 
some point during their treatment. Intensity-modulated radiotherapy 
(IMRT) is a technique that adds fluence modulation to beam shap-
ing, which improves radiotherapy dose conformity around the tumor 
and spares surrounding normal structures. Treatment with IMRT is 
becoming more widely available for the treatment of lung cancer, 
despite the paucity of high level evidence supporting the routine use 
of this more resource intense and complex technique. In this review 
article, we have summarized data from planning and clinical studies, 
discussed challenges in implementing IMRT, and made recommen-
dations on the minimum requirements for safe delivery of IMRT.
Key Words: Radiotherapy, Lung cancer, Intensity-modulated radio-
therapy, Non–small-cell lung cancer, Dose escalation.
(J Thorac Oncol. 2014;9: 1598–1608)
Radiotherapy plays an important role in the management of lung cancer, with over 50% of all lung cancer patients 
receiving this modality at some point during their treatment. 
In the radical setting, the ultimate aim of radiotherapy is to 
achieve local tumor control while limiting damage to the sur-
rounding normal tissue. The impact of local control in non–
small-cell lung cancer (NSCLC) has been highlighted by 
studies demonstrating that it correlates to a survival benefit.1,2
In the 1980s, the advent of computed tomography 
(CT) and the multileaf collimator (MLC) enabled radia-
tion oncologists to shape fields around a target volume with 
three-dimensional conformal radiotherapy (3DCRT) and 
this remains the standard procedure in lung radiotherapy.3 
However, despite advances in planning and verification, local 
progression-free survival and overall survival (OS) rates in 
locally advanced NSCLC remain low (30% and 10–15% at 5 
years, respectively).1,2,4
Currently, the standard dose/fractionation for patients 
with stage III NSCLC is 60 Gy equivalent dose in 2 Gy/frac-
tion (EQD2). One potential reason for low progression-free 
survival and OS rates in this group may be that this radiother-
apy dose is perhaps too low to achieve local control. Martel 
et al.5 estimated that doses of 84 Gy in EQD2 are required for 
50% probability of tumor control at 3 years, and biologically 
effective doses in excess of 100 Gy were needed to achieve 
greater than 90% local control in stereotactic ablative radio-
therapy (SABR) studies.6 These data suggest that higher bio-
logically effective doses may be required to achieve better 
local control, but evidence to support dose escalation using 
conventional fractionation is lacking in the current literature.7 
Despite this, many still believe that dose escalation in NSCLC 
could be of benefit, if facilitated by an improvement in radio-
therapy-delivery techniques.
Intensity-modulated radiotherapy (IMRT) is an advanced 
form of 3DCRT that modifies the intensity of the radiation across 
each beam in complex ways, sculpting the high-dose volume 
around the site of disease and thereby sparing adjacent organs at 
risk. The superior dose conformity that can be achieved allows 
avoidance of the surrounding normal tissues.8–14 This technique 
allows the treatment of radiotherapy volumes previously consid-
ered too large for a radical dose and permits safer dose escala-
tion to the tumor (potentially improving local control).
IMRT is currently being used routinely for the treatment 
of both early stage and locally advanced NSCLC in many inter-
national academic centers. However, there are no published ran-
domized trials comparing 3DCRT to IMRT in NSCLC15 and 
such studies are unlikely to be forthcoming. In the wider com-
munity, uptake of IMRT for lung cancer has been slow, which 
may in part be due to the relative lack of evidence in this field 
compared to head and neck and prostate cancer.16–19 Routine use 
of this technology also impacts on planning and treatment deliv-
ery times, and creates a need for equipment capable of facilitat-
ing image-guided treatment. Other considerations include how 
the “low-dose bath” created by the increased number of beam 
angles affect acute and late toxicity to the lung20 and second 
malignancy risk,21 and whether improved conformality to the 
target volume may in fact under-treat micrometastatic disease 
and lymph node stations previously incidentally treated to a 
therapeutic dose with 3DCRT.22
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In this article, we aim to give an overview of the ratio-
nale for IMRT in lung cancer, to present current evidence sup-
porting the use of this technique and finally to highlight future 
directions.
MATERIALS AND METHODS
This article is a review of the literature rather than a 
systematic review.
PubMed (1950–2014), EMBASE (1974–2014), and the 
Cochrane library were searched for phase I–III clinical trials, 
case-series studies, cohort studies, meta-analysis, and reviews 
in the English language using the following keywords: lung 
cancer, NSCLC, radiotherapy, radiation therapy, IMRT, and 
dose escalation.
Out of initial 118 articles identified by the search terms, 
46 were deemed eligible after screening by title and abstract 
review. In addition, relevant publications and conference 
abstracts known to the authors were also included.
What is IMRT?
IMRT adds fluence modulation to beam shaping,23–25 
which improves dose conformity around the tumor and 
spares surrounding normal structures.23,26 There are two main 
approaches to static IMRT and both deliver radiation from a 
number of fixed gantry angles and achieve fluence modula-
tion with different MLC arrangements. In its simplest form 
each IMRT field is segmented into a number of shaped sub-
fields (step and shoot approach). More complex sliding win-
dow techniques move the MLCs during “beam on” time. A 
further development is rotational IMRT or so-called volu-
metric-modulated arc therapy (VMAT), whereby the linear 
accelerator rotates around the patient, continually delivering 
radiation. As the MLCs change during this rotation, hundreds 
of fields are generated to create a more conformal dose distri-
bution.27 Tomotherapy represents another IMRT delivery tech-
nique,28 where dose is delivered using a technology similar to 
CT (slice-by-slice of helical dose delivery) combined with a 
binary MLC for fluency modulation.
3DCRT planning typically involves trialing different 
combinations of beam shapes, weights, and gantry angles until 
a satisfactory dose distribution is achieved (forward planning). 
This method is impractical for IMRT, due to the large numbers 
of fields requiring several MLC arrangements. Therefore, IMRT 
planning utilizes computerized inverse planning, whereby the 
desired dose distribution is described by a series of instructions 
to a computer system, which then uses a cost function to opti-
mize beam shapes, beam fluences, and beam weights to achieve 
the desired outcome. Advantages and disadvantages of using 
IMRT for lung cancer are presented in Table 1.
Dose Distributions with IMRT 
Compared to Conventional 3DCRT
A number of planning studies comparing dosimetric 
plan quality of 3DCRT and different IMRT techniques have 
been published in the field of lung cancer. These are summa-
rized in Table 2. All authors except McGrath et al.29 demon-
strate improved planning target volume (PTV) coverage with 
IMRT.8–14,30,31 Conversely, the literature reports mixed results 
with regards to doses to organs at risk. In general, IMRT 
reduces the volume of whole lung receiving more than 20 
Gy (V20),9–12,29–31 but the effect of IMRT on lower doses to 
the lung are not as clear; two groups report a reduction of 
V529,31, while another three groups report an increase.8,10,11 Of 
the groups who investigated the dose to the heart, four dem-
onstrated an advantage with IMRT8–10,12 and two did not find 
any benefit. When spinal cord dose was examined, five out of 
six groups found a significant advantage with IMRT.8,10,13,14,30
Table 3 compares different IMRT planning techniques. 
Apart from treatment time, there is no clear benefit for one 
technique above the others. All groups comparing standard 
IMRT techniques with VMAT found a treatment time advan-
tage in favor of VMAT.10,14,32–35 For example, Ong et al.13 
showed an 8-minute time reduction if VMAT was used com-
pared to IMRT. Weyh et al.35 compared tomotherapy, IMRT, 
and VMAT and reported a significant treatment time benefit 
using VMAT (6.5 minutes) compared to the other two tech-
niques (IMRT: 11.1 minutes, tomotherapy: 15.9 minutes). The 
clinical relevance of this, especially for SABR patients, is that 
treatment slots can be reduced from 30–40 minutes to signifi-
cantly shorter times.36,37 This shorter treatment time reduces 
the risk of intrafractional movement and maximizes on linear 
accelerator capacity.
Clinical Studies
Early-stage NSCLC
In 2010, Videtic et al.38 published clinical outcome data 
of medically inoperable stage I NSCLC patients treated with 
IMRT-based SABR. In this case series, 26 patients received 
50 Gy in 10 fractions, delivered with seven nonopposing, non-
coplanar-intensity modulated beams. The median heterogene-
ity index was 1.08 (range, 1.04–1.2). Seventy-one patients had 
histological confirmation and 89% of tumors were in a periph-
eral location (median size 2.2 cm). The treatment was well 
tolerated, with only one patient (who was on oxygen before 
commencement of treatment) experiencing grade 3 dyspnoea. 
Overall, there was no significant change in pulmonary func-
tion tests post-treatment and no treatment-related deaths. 
Three-year local control was comparable to surgical series and 
3DCRT-based SABR series at 94.4%, and 3-year OS was 52%.
Looking further into toxicity of IMRT for stage I NSCLC, 
Palma et al.39 compared radiological and clinical patterns of 
treatment-related pneumonitis (TRP) in patients who received 
SABR delivered either with VMAT (a rotational form of IMRT 
using up to 5 arcs) or 3DCRT (8–12 noncoplanar static beams). 
Seventy-five patients (25 VMAT, 50 3DCRT) were included in 
the study. Patients between the two arms were matched demo-
graphically, for dose, fractionation, PTV size (<100 cc), and 
tumor location. Interestingly, although 57% patients developed 
radiological changes in the lung, only 5% developed clinical 
symptoms. The toxicity profile is similar to that of 3DCRT-
based SABR. There was no statistically significant difference 
between the groups in terms of the rate of clinical TRP.
Ong et al.13 compared VMAT, IMRT, 3DCRT, and 
dynamic conformal arc techniques for SABR of stage I 
NSCLC. Although all met the normal tissue dose constraints, 
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IMRT was useful in further shaping the beam around critical 
organs at risk e.g., chest wall and VMAT had an advantage 
over other techniques in terms of dose conformity and treat-
ment time. A further paper by the same group reported on a 
retrospective series of 18 patients with large volume (median 
PTV 137 cm3), stages I–II lung tumors without nodal metasta-
ses treated with VMAT.40 A risk-adapted fractionation scheme 
of either five fractions of 11 Gy or eight fractions of 7.5 Gy 
was used with the following planning objectives: 95% of the 
PTV should receive at least the nominal fraction dose, 99% 
of the target volume should receive greater than or equal to 
90% of the prescription dose, and the maximum PTV dose 
was between 110% and 140% of the prescription dose. Five 
patients developed grade of greater than or equal to 2 radia-
tion pneumonitis (three with grade 2 and two with grade 3), all 
cases occurred in plans without a high priority optimization 
objective on contralateral lung. They demonstrated that acute 
TRP was best predicted by contralateral lung V5 (p < 0.0001).
Locally advanced NSCLC
Prospective studies. A potential advantage of IMRT over 
3DCRT is the ability to safely escalate radiotherapy dose. One 
of the first studies to address this issue was a phase I dose 
escalation study (84 Gy/35 fractions) of IMRT in stage III 
NSCLC and induction chemotherapy.41 This study was halted 
after the enrolment of five patients as one patient died of pneu-
monitis. This may have been due to an adverse effect of che-
motherapy on baseline lung function or the hypofractionated 
dose regime; however, this study has been criticized for using 
an inadequate dose calculation algorithm, leading to system-
atic underestimation of doses to the tumor and organs at risk.42
It was widely anticipated that RTOG 0617, a prospective, 
randomized phase III trial comparing 60 Gy/30 daily fractions 
with 74 Gy/37 daily fractions (concurrently with paclitaxel/car-
boplatin), with or without cetuximab would be the first phase 
III trial to confirm the benefit of dose escalation beyond 60 
Gy in stage III NSCLC.7 Surprisingly, at interim analysis the 
data suggested a survival disadvantage for the high-dose arm 
as well as inferior local control rates, indicating that dose esca-
lation using conventional fractionation (resulting in increased 
overall treatment time) is not the ideal approach for NSCLC. 
The reasons for this are the subject of some debate, but possible 
explanations include: increased heart dose, extended therapy 
duration, underreported grade 5 events, compromised target 
coverage, or likely a combination of these factors. It should 
be noted that just under half of the patients in this study were 
treated with IMRT (46.5%). Although patients were stratified 
by treatment delivery technique and the proportions of patients 
treated with IMRT were balanced between treatment groups 
(46.1% in 60 Gy arms and 47.1% in 74 Gy arms), the deliv-
ery of 74 Gy was probably challenging, particularly in patients 
treated without IMRT, given the gross tumor volume (GTV) 
(mean 124.7 in 60 Gy arms and 128.5 cc in 74 Gy arms). A 
subsequent analysis on patient reported outcome demonstrated 
a significantly worse quality of life on the 74 Gy arms at 3 
months after treatment.43 Interestingly, the decline in quality of 
life was significantly reduced with the use of IMRT compared 
to 3DCRT suggesting that the use of improved radiotherapy 
treatment techniques may be beneficial.
More recently, results of a phase I trial of hypofrac-
tionated, dose escalating IMRT in NSCLC were published.44 
Seventy-nine patients received dose escalated treatments 
based on the patients’ stratified risk for TRP in 25 daily 
fractions. Patients with all stages of disease were recruited 
and 62% received chemotherapy in the neoadjuvant or adju-
vant setting. Patients were all positron emission tomography 
staged, planned using four-dimensional (4D) CT and the 
treatment was delivered with helical tomotherapy. The dose 
was prescribed such that 95% of the PTV volume received 
the prescription dose. Despite escalation to doses of up to 
85.5 Gy/25 fractions, no grade 3 acute or late esophageal 
toxicity and no grade 3 pneumonitis was seen; however, six 
grade 4/5 toxicities were encountered in the form of mas-
sive hemoptysis and bronchocavitary fistula. Both these tox-
icities were associated with centrally based tumors, doses 
above 75 Gy, and specific 1–3 cc doses to the proximal 
bronchial tree. No constraints for proximal bronchial tree 
were specified in the trial protocol. After a median follow-
up of 17 months median survival was 16 months and 3-year 
OS was 29%, which does not appear superior to historical 
outcome.
Retrospective studies. The largest body of evidence for IMRT 
in locally advanced NSCLC originates from three retrospective 
publications of patient cohorts from the same cancer center (MD 
TAbLE 1.  Advantages and Disadvantages of IMRT for Lung Cancer
Advantages Disadvantages
Ability to spare organs at risk Increased contouring, planning, and quality assurance time
Better coverage of irregular shaped targets Increased need to accurately delineate clinical target volumes and involved nodes 
requiring treatment
Ability to dose escalate Need for image guidance
Able to treat synchronous primary tumors and multiple targets 
simultaneously
Sharp dose gradient—may lead to under-treatment of micrometastatic disease
Enables treatment of larger radiotherapy volumes to radical dose Potential interplay effects depending on fractionation and complexity of IMRT 
technique used
Need for rigorous quality assurance programme
Low-dose radiotherapy bath
IMRT, intensity-modulated radiotherapy.
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Anderson Cancer Centre, Texas). It should be emphasized that 
as the treatment groups were not fully balanced and positron 
emission tomography staging was introduced at the time of re-
cruitment to the IMRT cohorts, the data need to be interpreted 
with caution. Nevertheless, these studies all suggested improved 
outcomes with IMRT, reporting less toxicity and a superior OS.
Yom et al.45 evaluated the rate of TRP in 68 NSCLC 
patients (85% stage III) treated with IMRT between 2002 and 
2005, and compared this to a group of 222 historical controls 
treated with 3DCRT (2000–2003). Reasons for implementing 
IMRT included large treatment volume, failure to meet nor-
mal tissue dose constraints for 3DCRT, synchronous lung pri-
mary tumors, and poor baseline pulmonary function. In both 
groups, the majority of patients received a treatment dose of 
63 Gy in 35 fractions and concurrent platinum-based doublet 
chemotherapy. Despite a larger GTV in the IMRT group (194 
versus 142 cc), patients achieved significantly lower volumes 
of lung receiving 20 Gy (V20), however had larger volumes of 
lung receiving 5 Gy (V5) compared to the 3DCRT group. With 
a median follow-up of eight (0–27) and nine (0–56) months, 
respectively, the incidence of greater than grade 3 TRP was 
significantly lower in the IMRT group than in those treated 
with 3DCRT (8% versus 22% at 6 months). Local control in 
the IMRT group at 12 months was 55.3% with an estimated 
OS at 12 months of 57%.
Liao et al.46 examined the effect of IMRT, accounting 
for motion (4DCT), on toxicity and clinical outcome in locally 
advanced NSCLC. Ninety-one patients (some of whom were 
also included in the Yom study) were treated with 4DCT/
IMRT between 2004 and 2006. These were compared to 318 
patients receiving 3DCRT between 1999 and 2004. Both 
groups received a median dose of 63 Gy using conventional 
fractionation. The IMRT group contained a greater propor-
tion of patients who were older, current smokers, or staged 
with positron emission tomography CT (82% 4DCT IMRT 
versus 49% 3DCTRT). GTV was not reported. Again, this 
study confirmed a reduced rate of TRP in the IMRT group, 
with significantly lower V20 percentages (34% versus 37%), 
at the expense of a higher V5 (65% versus 57%). The authors 
reported similar rates of local control and distant metastases, 
but an improvement in OS in the IMRT group (median sur-
vival times 1.40 years for the 4DCT/IMRT group and 0.85 
year for the 3DCRT group).
Their most recent study assessed long-term clini-
cal outcome of patients treated with 4DCT IMRT (n = 165; 
76% stage III) with or without concurrent chemotherapy. The 
median radiation dose was 66 Gy given in 33 fractions47 and 
median GTV was 124.6 cc (range, 4.3–730 cc). Eleven per-
cent of patients developed greater than or equal to grade 3 
TRP at 6 months and one patient was affected by grade 3 pul-
monary fibrosis at 18 months. The majority of the 29 patients 
(18%), who experienced grade 3 esophagitis settled within 6 
weeks, however four went on to develop an esophageal stric-
ture requiring further intervention. Overall, the incidence and 
severity of toxicities were lower in IMRT patients than histori-
cal control cohorts who received 3DCRT. With a median 16.5 
months follow-up, 2-year disease free and OS were 38% and 
46%, respectively.
Other centers have also published encouraging ret-
rospective outcome data for IMRT in locally advanced 
NSCLC. Memorial Sloan Kettering assessed the toxicity of 
IMRT in 55 stages Ib–IIIb (62% stage III) NSCLC patients 
between 2001 and 2005.48 Patients received a dose of 60 
Gy in 30 fractions with either sequential (53%) or concur-
rent (24%) chemotherapy, unless contraindicated. Mean 
GTV was 136 cc. With a median follow-up of 12 months, 
six (11%) patients reported grade 3 pulmonary toxicity, and 
two (4%) developed grade 3 esophageal toxicity. Two-year 
OS was 58% with a median survival of 25 months. Govaert 
et al.49 experienced similar findings in 71 stages IIb–IIIb 
NSCLC patients treated with IMRT between 2008 and 2011. 
Patients received up to a dose of 66 Gy in 33 fractions with 
chemotherapy. Mean GTV volume was not reported. No 
grade 3/4 pulmonary or esophageal toxicity was observed, 
and there were no treatment-related deaths. After median 
follow-up of 12 months, median survival was 29.7 months, 
which translated to a 56% two-year OS. A group at the 
Netherlands Cancer Institute assessed at the rate of acute50 
and late51 toxicity following hypofractionated IMRT (66 Gy 
in 24 fractions) and concurrent chemotherapy for NSCLC 
in two separate papers. Thirty-five percent of patients devel-
oped any greater than grade 3 acute toxicity and 7% patients 
developed TRP. Six percent (11/171) developed severe late 
esophageal toxicity in the form of stenosis (8/11) or fistula 
(3/11), which was comparable to historical cohorts treated 
with 3DCRT. Two-year OS was 52%.
Population-based studies. Shirvani et al.52 investigated pre-
dictors of IMRT use in the United States between 2001 and 
2007, using the Surveillance, Epidemiology, and End Results 
(SEER) Medicare database. They reported that the year of 
diagnosis and treatment in a dedicated radiotherapy center 
were the only independent predictors of IMRT use. Lung and 
esophageal toxicity was equal between the IMRT and 3DCRT 
groups. A further population-based study using the SEER da-
tabase compared treatment outcomes in stage III NSCLC for 
IMRT, 3DCRT, and two-dimensional radiotherapy (2DRT) 
planning techniques.53 This study was conducted to address 
fears that IMRT may cause inaccuracies in dose and increased 
long-term toxicity, which in turn could affect survival. This 
analysis of nearly 7000 patients confirmed that IMRT was as-
sociated with similar toxicities and OS to 3DCRT, with both 
techniques showing an advantage over 2DRT.
Challenges in implementing IMRT
Although the majority of planning studies and limited clinical 
data support the use of IMRT in lung cancer, implementation 
comes with clinical and technical challenges. IMRT is a more 
complex technique than conventional 3DCRT23 and places 
higher demands on treatment planning, dose calculation al-
gorithms, and delivery systems. As IMRT relies on computer-
ized inverse planning, additional organs at risk such as the 
heart, brachial plexus, central airways, and esophagus need to 
be contoured to instruct the system to avoid depositing high 
dose in these tissues. This is time consuming for the clinician 
and the treatment planner.54,55
1604 Copyright © 2014 by the International Association for the Study of Lung Cancer
Chan et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 11, November 2014
Dose calculation in lung tissue requires the use of a 
model-based calculation algorithm (type B), as use of mea-
surement-based algorithms (type A) give rise to inaccurate 
scatter modeling in lung tissue and deviations of up to 5% 
between calculated and measured doses.56–58 Discrepancies 
between type A algorithms and measurements are larger for 
IMRT compared to 3DCRT59 and so the use of type B algo-
rithms is a prerequisite when planning IMRT for lung patients. 
The increased complexity of IMRT plans also require addi-
tional quality assurance tests to be routinely performed on the 
delivery system (and commonly across Europe, on individual 
patient plans).60–62
Breathing motion, especially in lung cancer, influences 
the dose delivered to the patient. This variation with respira-
tion creates two organ motion effects: the gradient/blurring 
effect and the interplay effect. The gradient effect occurs as 
the tumor moves, “blurring” the area in which the tumor is 
in. This effect can be compensated for by radiating the whole 
envelope of motion (within an internal target volume),63,64 by 
calculating a margin based on the probability distributions of 
the cumulative dose65 or by a tracking or gating technique.66,67 
The interplay effect is caused by the lack of synchrony 
between the moving aperture (e.g., MLC) and tumor motion. 
There is concern that the highly conformal fields, numerous 
MLC positions required for IMRT and intra-fractional tumor 
motion may lead to target miss. Several authors have evalu-
ated the interplay effect for conventional fractionated IMRT 
treatments using sinusoidal motion34,68–73 as well as realis-
tic patient motion.66–68 All reported that the interplay effect 
could alter the dose distribution of a single fraction, but not 
a fractionated course of treatment. Jiang et al.34 demonstrated 
a maximum dose variation of 30% for one field in one frac-
tion, 18% for all five fields after one fraction, and less than 
1–2% after 30 fractions. Even with SABR there is a negligible 
interplay effect as effects average out due to the larger number 
of monitor units and increased treatment time required.74–76 
However, interplay may cause an effect for extreme hypofrac-
tionation/SABR combined with very complex IMRT/VMAT 
deliveries. Strategies to reduce the interplay effect include 
increasing the number of arcs,74 decreasing the dose rate and 
therefore prolonging the treatment time34 or avoiding an MLC 
motion perpendicular to the tumor motion.74
In comparison to 3DCRT, IMRT increases the low-dose 
bath to the patient as a greater number of beams and moni-
tor units are used (an increase in monitor units is necessary 
to compensate for large parts of the fields being blocked by 
MLCs and this increases head leakage and scatter radiation). 
There are concerns that this low-dose bath may increase the 
risk of acute and late pulmonary toxicity, as well as the risk 
of second malignancy.11,21,23,77 The potential survival benefit 
of IMRT outweighs the secondary cancer risk in NSCLC, 
however toxicity is of importance. A correlation between low 
doses to the lung and fatal pneumonitis has been demonstrated 
in mesothelioma, leading to recommended threshold doses of 
FIguRE 1.  Patient with large volume 
disease (T3N3M0) treated with seven 
fields fixed-beam step and shoot IMRT. 
66 Gy in 33 fractions prescribed to 
PTV_IMRT (PTV edited from the skin 
by a 0.5 cm isotropic 3D margin and 
from the spinal canal by a 1.0 cm 
isotropic 3D margin). Mean lung dose 
19.9 Gy, V20 34.5%, maximum spinal 
cord 48.9 Gy. PTV, planning target 
volume; V20, percent volume of total 
lung receiving 20 Gy; IMRT, intensity-
modulated radiotherapy; 3D, three 
dimensional.
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mean lung dose of less than 8.5–13 Gy, V5 less than 60–75%, 
and V10 less than 50%.20,78,79 However, a clear relationship 
between V5 lung doses and severe pulmonary toxicity for 
IMRT in NSCLC is lacking and as yet there is no consensus 
as to suitable threshold doses.
DISCuSSION AND FuTuRE DIRECTIONS
By facilitating improved beam shaping around complex 
structures, IMRT offers the potential to optimize dose delivery 
to a target volume while sparing surrounding normal tissue. 
This increases the scope to safely escalate the dose, boost sub-
volumes, and treat larger radiotherapy volumes in the radical 
setting than was previously possible with 3DCRT (Fig. 1).
The key clinical question regarding this technique is 
whether IMRT can lead to an improvement in OS as a result 
of reduced toxicity and/or isotoxic dose escalation (individ-
ualized dose escalation based on predefined safe organs at 
risk dose constraints) leading to improved local tumor con-
trol. Patients with a high burden of disease may relapse both 
locally and distantly, making outcomes similar whether or not 
the dose to the primary has been optimized. Robust, random-
ized evidence demonstrating improved clinical outcomes with 
IMRT is lacking, and concerns regarding the need for extra 
resources in terms of treatment planning, delivery time, and 
financial cost may go some way to explain why the uptake of 
this technique remains low.15
There is little doubt from planning studies that there is 
a dosimetric advantage of using IMRT for lung cancer, which 
should justify the increase in time requirements for contour-
ing, planning, and treatment verification. A specific concern 
about the use of IMRT for lung is the amount of tumor motion 
during treatment seen in this site compared to, for example, 
head and neck cancers. This can be partly remedied with 
4DCT and advanced planning techniques, and encourag-
ingly the interplay effect does not seem to cause any clinical 
detriment.
We would argue that the clinical evidence reviewed in 
this article demonstrate that IMRT can be delivered safely 
with acceptable acute and late toxicities. IMRT facilitates 
lowering of critical dosimetric parameters such as V20, and 
although lower doses of radiation are delivered to more tissue, 
concerns that this “low-dose bath” may adversely affect long-
term lung function or increase second malignancy risk have 
not been reported in prospective studies. Crucially retrospec-
tive studies report disease-free and OS figures which seem 
to show an advantage over those achieved with conventional 
3DCRT. As these studies were not randomized, there is a like-
lihood of inherent bias. The IMRT cohorts will have been 
treated more recently meaning that stage migration may play a 
part in the improved survival as well as improved patient setup 
imaging such as Cone Beam CT. Conversely, as IMRT was 
initially often used for patients unable to meet 3DCRT dose 
constraints, this group may also contain a higher risk popula-
tion that would have been expected to have a lower survival.
The outcome of the recent RTOG 0617 study showing 
no benefit for the higher dose arm has left some questioning 
efforts to dose escalate in lung cancer radiotherapy. Although 
on face value it would seem that the “dose escalation in lung 
cancer” debate has stalled, we need to be cautious not to dis-
miss “radiotherapy treatment intensification” as a concept. 
There are many unanswered questions surrounding RTOG 
0617 regarding dose delivery and radiotherapy quality assur-
ance and it is important to acknowledge that less than 50% 
patients in this trial were treated with IMRT. In addition, there 
TAbLE 4.  Examples of Ongoing Clinical Trials Utilizing IMRT for Dose Escalation
Trials Evaluating Personalized Dose  
Escalation Based on Dose Delivered to OARs
Trials Evaluating an Increased Dose to Selected Parts Within  
the Tumor, Defined by Functional Imaging (Dose Painting)
Isotoxic IMRT (NCT01836692) PET boost (NCT01024829)
Prospective multicenter single arm feasibility study Randomized multicenter phase II study
Stage III NSCLC T2-4, N0-3, M0 inoperable, NSCLC
Sequential chemoradiotherapy RT alone, sequential, or concurrent chemoradiotherapy
Hyperfractionated, accelerated, and dose-escalated radiotherapy with  
IMRT and image guidance. Dose based on prespecified normal  
tissue doses
66 Gy given in 24 fractions of 2.75 Gy delivered with IMRT +/- integrated 
boost to whole tumor, or the FDG PET-CT 50% SUV
max
 area of the primary 
individualized to meditational organs at risk (with or without chemotherapy)
Maximum dose 79.4 Gy in 39 twice-daily (BD) fractionsPrimary  
outcome: delivery of isotoxic IMRT to dose >60 Gy EQD2 (total 
biologically equivalent in 2 Gy fraction)Proceed to phase II if dose 
escalation possible in >80% patients
Primary outcome: local progression-free survival at 1 yearThe planning results 
of the first 20 patients have been published. It was possible to dose escalate 
75% of patients to 72Gy, with dose-limiting organs being the mediastinal 
structures and the brachial plexus80
Maastro study (NCT01166204) RTOG (NCT01507428)
Nonrandomized monocenter phase II study Randomized multicenter phase II study
Stages I–III NSCLC Stage III NSCLC
Concurrent chemoradiotherapy Concurrent chemoradiotherapy
Radiotherapy delivered with IMRT to an individualized mean lung  
dose of 20 Gy +/-1
60 Gy in 30 daily fractions delivered with IMRT +/- adaptive radiotherapy based 
on FDG-PET/CT scan between fractions 18 and 19
45Gy/30 BD fractions for first 3 weeks followed by once daily  
fractions of 2 Gy until the target dose has been reached
Max dose 80.4 Gy in 30 daily fractions, individualized to mean lung dose 20 Gy
Primary outcome: overall survival Primary outcome: local progression-free survival
IMRT, intensity-modulated radiotherapy.
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remains good evidence to show that improved local control 
can improve survival. There is therefore a general consen-
sus that radiotherapy treatment intensification with advanced 
radiotherapy techniques and image guidance still represents 
a valuable opportunity to improve outcomes for lung cancer 
patients. The situation however is complex, with consider-
ation for different fractionation regimes and perhaps a move 
to greater individualization of treatment. To this end a number 
of clinical trials to address these issues are open or in set up; 
examples of these are presented in Table 4.
In conclusion, from the current evidence available, 
IMRT can achieve better dose conformality, avoid organs 
at risk and lower treatment toxicity. However, compared to 
conventional 3D techniques, the planning process and treat-
ment delivery is time consuming and places strain on valuable 
resources. Our recommendations for the minimum require-
ments to deliver IMRT safely are presented in Table 5. Further 
prospective data are needed to strengthen the evidence base 
for this technique. It is hoped that eventually we may be able 
to correlate clinical features of the tumor and radiotherapy 
planning parameters with toxicity and survival. At present 
IMRT is best indicated when the tumor volume is near to an 
organ at risk or when treatment volumes are too large to treat 
to a radical dose with 3DCRT. However, research activity into 
dose escalation for lung cancer is intensifying and once the 
optimal approach to this is established, IMRT will undoubt-
edly play an essential role in radiotherapy treatment delivery.
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